Defining a correlate of protection for chikungunya virus vaccines.
Animals
Antibodies, Neutralizing
/ biosynthesis
Antibodies, Viral
/ biosynthesis
Biomarkers
Biomedical Research
/ organization & administration
Chikungunya Fever
/ immunology
Chikungunya virus
/ drug effects
Clinical Trials as Topic
Disease Models, Animal
Disease Outbreaks
Humans
Macaca fascicularis
Mice
Technology Transfer
Vaccination
/ methods
Viral Vaccines
/ administration & dosage
Animal models
Arbovirus
Assays
Clinical trial
Neutralizing antibodies
Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
28 11 2019
28 11 2019
Historique:
received:
09
02
2018
accepted:
08
10
2018
pubmed:
19
11
2018
medline:
23
7
2020
entrez:
19
11
2018
Statut:
ppublish
Résumé
Chikungunya virus infection causes a debilitating febrile illness that in many affected individuals is associated with long-term sequelae that can persist for months or years. Over the past decade a large number of candidate vaccines have been developed, several of which have now entered clinical trials. The rapid and sporadic nature of chikungunya outbreaks poses challenges for planning of large clinical efficacy trials suggesting that licensure of chikungunya vaccines may utilize non-traditional approval pathways based on identification of immunological endpoint(s) predictive of clinical benefit. This report reviews the current status of nonclinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection.
Identifiants
pubmed: 30448337
pii: S0264-410X(18)31399-9
doi: 10.1016/j.vaccine.2018.10.033
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Biomarkers
0
Viral Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7427-7436Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.